Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?

Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?

Bibliographic Details
Main Author:	I. Galal
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2014-10-01
Series:	Egyptian Journal of Chest Disease and Tuberculosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S0422763814001460

Similar Items

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
by: Alberto Aimo, et al.
Published: (2022-04-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Arata Azuma
Published: (2012-04-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011-02-01)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
by: Takeda Y, et al.
Published: (2014-03-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
by: Esam H Alhamad
Published: (2015-01-01)

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
by: Aahd Kubbara, et al.
Published: (2023-08-01)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
by: Lisa H. Lancaster, et al.
Published: (2017-12-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
by: Goran Nadir Salih, et al.
Published: (2016-09-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
by: Carlos Aravena, et al.
Published: (2015-01-01)

Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models
by: Wencheng Yu, et al.
Published: (2017-01-01)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
by: Manon Belhassen, et al.
Published: (2021-05-01)

Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?
by: S. Campainha, et al.
Published: (2016-03-01)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2017-11-01)

Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis
by: Kiran Dudhat, et al.
Published: (2022-06-01)

Correction: Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
by: Carlos Aravena, et al.
Published: (2015-01-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
by: Kazutaka Takehara, et al.
Published: (2022-01-01)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2018-01-01)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
by: Sakayori M, et al.
Published: (2019-07-01)

Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
by: Gulati S, et al.
Published: (2020-05-01)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
by: Sahajal Dhooria, et al.
Published: (2015-01-01)

Comparative study between pirfenidone and traditional drugs in treatment of idiopathic pulmonary fibrosis
by: Ramadan M Nafee, et al.
Published: (2019-01-01)

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis
by: Meishan Han, et al.
Published: (2022-04-01)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
by: Pavo Marijic, et al.
Published: (2021-10-01)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
by: Cheng-Yu Chang, et al.
Published: (2023-10-01)

Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels
by: Yasuhiko Koga, et al.
Published: (2019-05-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
by: Hui Li, et al.
Published: (2022-11-01)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
by: Vincent Cottin, et al.
Published: (2015-03-01)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
by: C. C. Moor, et al.
Published: (2020-07-01)

Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study
by: Myung Jin Song, et al.
Published: (2021-05-01)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019-01-01)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021-08-01)

Effects of comorbid chronic kidney disease on mortality in idiopathic pulmonary fibrosis patients and influence of pirfenidone
by: Yong Suk Jo, et al.
Published: (2023-11-01)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)

Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone
by: Tae Hun Kim, et al.
Published: (2022-10-01)

Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
by: Lina Marcela Barranco-Garduño, et al.
Published: (2020-10-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study
by: Martina Doubkova, et al.
Published: (2021-09-01)